Table 2.

Clinical and genotypic data of the patients- 35 patients were screened for the mutation and 3 were died prior to the genetic confirmation. (AMN: Adrenomyeloneuropathy; ccALD: Childhood cerebral ALD).

No	Pedigree Code	Age	Sex	Genotype	Phenotype	Others
1	III-2	-	Female	Carriers	-	-
2	III-3	88	Female	Carriers	Asymptomatic	-
3	III-10	73	Female	Carriers	Asymptomatic	-
4	IV-3	-	Female	Carriers	-	-
5	IV-11	57	Female	Carriers	Asymptomatic	-
6	IV-13	60	Female	Carriers	Asymptomatic	-
7	IV-16	55	Female	Carriers	AMN	-
8	IV-18	43	Female	Carriers	AMN	-
9	IV-21	54	Female	Carriers	AMN	-
10	IV-26	36	Female	Carriers	Asymptomatic	-
11	V-4	7	Female	Carriers	Asymptomatic	-
12	V-11	28	Female	Carriers	Asymptomatic	-
13	V-14	29	Female	Carriers	Asymptomatic	Β-Thalassemia minor
14	V-30	5	Female	Carriers	Asymptomatic	-
15	VI-1	10	Female	Carriers	Asymptomatic	-
16	VI-4	16	Female	Carriers	Asymptomatic	Β-Thalassemia minor
17	V-23	32	Female	Affected	Asymptomatic	-
18	V-26	21	Female	Affected	Asymptomatic	-
19	V-28	Dead by 11 yr;	Female	Affected	ccALD	Dead before screening
20	V-29	22	Female	Affected	AMN	-
21	IV-1	Dead by 15 yr;	Male	Affected	ccALD	Dead before screening
22	IV-9	41	Male	Affected	AMN	-
23	IV-15	15	Male	Affected	AD	-
24	IV-19	57	Male	Affected	AMN	Primary diagnosis and treatment of MS
25	IV-27	36	Male	Affected	Asymptomatic	-
26	V-3	26	Male	Affected	-	-
27	V-6	Dead by 26 yr;	Male	Affected	AMN	Dead before screening
28	V-7	45	Male	Affected	Asymptomatic	-
29	V-13	23	Male	Affected	AMN	-
30	V-25	24	Male	Affected	Asymptomatic	-
31	V-27	21	Male	Affected	Asymptomatic	-
32	V-33	27	Male	Affected	Asymptomatic	-
33	V-36	24	Male	Affected	Asymptomatic	-
34	V-43	8	Male	Affected	ccALD	Treated with stem cells but dead by 11 yr
35	V-44	7	Male	Affected	Asymptomatic	-
36	IV-22	45	Male	Genetically unaffected	AMN	-
37	V-19	21	Female	Genetically unaffected	Asymptomatic	Β-Thalassemia minor
38	V-20	34	Female	Genetically unaffected	Asymptomatic	Β-Thalassemia minor